Salivary Glucose Levels Measured by Biochip Sensor
|
By LabMedica International staff writers Posted on 18 Jun 2014 |

Image: The schematic shows glucose molecules sliding along the biochip sensor surface illuminated by different colors. Change in light intensity transmitted through the slits of each plasmonic interferometer can be used to measure the glucose concentration in saliva (Photo courtesy of Domenico Pacifici, PhD).
A new biochip sensor has been developed that can selectively measure concentrations of glucose in a complex solution similar to human saliva.
The new chip makes use of a series of specific chemical reactions combined with plasmonic interferometry which is a means of detecting chemical signature of compounds using light. The device is sensitive enough to detect differences in glucose concentrations that amount to just a few thousand molecules in the sampled volume.
Scientists at Brown University (Providence, RI, USA) exploited the synergistic advantage of combining plasmonic interferometry with an enzyme-driven dye assay that yields an optical sensor capable of detecting glucose in saliva with high sensitivity and selectivity. The biochip is made from a 2.54 x 2.54-cm piece of quartz coated with a thin layer of silver. Etched in the silver are thousands of nanoscale interferometers, tiny slits with a groove on each side. The grooves measure 200 nm wide and the slit is 100 nm wide.
When a liquid is deposited on the chip, the light and the surface plasmon waves propagate through that liquid before they interfere with each other. That alters the interference patterns picked up by the detectors, depending on the chemical makeup of the liquid. The scientists added microfluidic channels to the chip to introduce two enzymes that react with glucose in a very specific way. The first enzyme, glucose oxidase, reacts with glucose to form a molecule of hydrogen peroxide. This molecule then reacts with the second enzyme, horseradish peroxidase, to generate a molecule called resorufin, which can absorb and emit red light, thus coloring the solution. The team could then tune the interferometers to look for the red resorufin molecules.
The team tested its combination of dye chemistry and plasmonic interferometry by looking for glucose in artificial saliva, a mixture of water, salts and enzymes that resembles the real human saliva. They found that they could detect resorufin in real time with great accuracy and specificity. They were able to detect changes in glucose concentration of 0.1 μM/L, which is 10 times the sensitivity that can be achieved by interferometers alone. The proposed device is highly sensitive and highly specific for glucose sensing in picoliter volumes, across the physiological range of glucose concentrations found in human saliva, which is 20 μM–240 μM.
Domenico Pacifici, PhD, an assistant professor of engineering, and who led the study, said, “We have demonstrated the sensitivity needed to measure glucose concentrations typical in saliva, which are typically 100 times lower than in blood. Now we are able to do this with extremely high specificity, which means that we can differentiate glucose from the background components of saliva.” The study was published in the June 2014 edition of the journal Nanophotonics.
Related Links:
Brown University
The new chip makes use of a series of specific chemical reactions combined with plasmonic interferometry which is a means of detecting chemical signature of compounds using light. The device is sensitive enough to detect differences in glucose concentrations that amount to just a few thousand molecules in the sampled volume.
Scientists at Brown University (Providence, RI, USA) exploited the synergistic advantage of combining plasmonic interferometry with an enzyme-driven dye assay that yields an optical sensor capable of detecting glucose in saliva with high sensitivity and selectivity. The biochip is made from a 2.54 x 2.54-cm piece of quartz coated with a thin layer of silver. Etched in the silver are thousands of nanoscale interferometers, tiny slits with a groove on each side. The grooves measure 200 nm wide and the slit is 100 nm wide.
When a liquid is deposited on the chip, the light and the surface plasmon waves propagate through that liquid before they interfere with each other. That alters the interference patterns picked up by the detectors, depending on the chemical makeup of the liquid. The scientists added microfluidic channels to the chip to introduce two enzymes that react with glucose in a very specific way. The first enzyme, glucose oxidase, reacts with glucose to form a molecule of hydrogen peroxide. This molecule then reacts with the second enzyme, horseradish peroxidase, to generate a molecule called resorufin, which can absorb and emit red light, thus coloring the solution. The team could then tune the interferometers to look for the red resorufin molecules.
The team tested its combination of dye chemistry and plasmonic interferometry by looking for glucose in artificial saliva, a mixture of water, salts and enzymes that resembles the real human saliva. They found that they could detect resorufin in real time with great accuracy and specificity. They were able to detect changes in glucose concentration of 0.1 μM/L, which is 10 times the sensitivity that can be achieved by interferometers alone. The proposed device is highly sensitive and highly specific for glucose sensing in picoliter volumes, across the physiological range of glucose concentrations found in human saliva, which is 20 μM–240 μM.
Domenico Pacifici, PhD, an assistant professor of engineering, and who led the study, said, “We have demonstrated the sensitivity needed to measure glucose concentrations typical in saliva, which are typically 100 times lower than in blood. Now we are able to do this with extremely high specificity, which means that we can differentiate glucose from the background components of saliva.” The study was published in the June 2014 edition of the journal Nanophotonics.
Related Links:
Brown University
Latest Clinical Chem. News
- New CA19-9 Cutoff Value Helps Identify High-Risk Pancreatic Cancer Patients
- Blood-Based Biomarkers Show Promise for Psychosis Risk Prediction
- International Experts Recommend Ending Routine 'Corrected' Calcium Reporting
- Long-Term Data Show PSA Screening Modestly Reduces Prostate Cancer Deaths
- Urine-Based Nanosensor Tracks Lung Cancer and Fibrosis Noninvasively
- FDA-Cleared Assay Enables Comprehensive Automated Testosterone Testing
- CE-Marked Blood Biomarker Test Advances Automated Alzheimer’s Diagnostics
- Blood-Based Alzheimer’s Test Gains CE Mark for Amyloid Pathology Detection
- Noninvasive Urine Test May Support Earlier Diagnosis of Psychiatric Disorders
- At-Home Blood and Cognitive Tests Support Dementia Risk Stratification
- Ultrasensitive Test Detects Key Biomarker of Frontotemporal Dementia Subtype
- Routine Blood Tests Years Before Pregnancy Could Identify Preeclampsia Risk
- Blood Test Detects Testicular Cancer Missed by Standard Markers
- Routine Blood Tests Identify Biomarkers Linked to PTSD
- Proteomic Data Underscore Need for Age-Specific Pediatric Reference Ranges
- Routine Blood Count Ratio Linked to Future Alzheimer’s and Dementia Risk
Channels
Molecular Diagnostics
view channel
New RNA Origami Method Supports Faster Targeted Testing for Repeat Expansion Disorders
Repeat expansion disorders drive conditions such as myotonic dystrophy, Huntington’s disease, and amyotrophic lateral sclerosis (ALS), yet accurately sizing the mutated sequences remains difficult.... Read more
FDA Approves Expanded Liquid Biopsy Panel for Advanced Cancer Profiling
Timely, comprehensive tumor profiling helps clinicians make treatment selection decisions for patients with advanced cancer. Blood-based approaches can provide actionable insights from a simple draw and... Read moreHematology
view channel
Higher Ferritin Threshold May Improve Iron Deficiency Detection in Children
Iron deficiency in school-age children can affect brain development, learning, growth, and physical performance, yet early deficiency may be missed when screening focuses mainly on anemia.... Read more
Stem Cell Biomarkers May Guide Precision Treatment in Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is an aggressive blood cancer that most often affects older adults and still carries a poor prognosis despite therapeutic advances. Venetoclax-based regimens have improved... Read moreImmunology
view channel
Immune Enzyme Linked to Treatment-Resistant Inflammatory Bowel Disease
Inflammatory bowel disease (IBD) affects nearly 3 million people in the United States and its prevalence continues to rise. Medications that target tumor necrosis factor (TNF)-alpha are widely used, but... Read more
Simple Blood Test Could Replace Biopsies for Lung Transplant Rejection Monitoring
Lung transplant recipients face some of the highest rates of acute cellular rejection, and routine surveillance often relies on repeated surgical biopsies. These procedures can cause complications such... Read moreMicrobiology
view channel
New AMR Assay Supports Rapid Infection Control Screening in Hospitals
As antimicrobial resistance spreads worldwide, healthcare-associated infections are placing a growing burden on hospitals, increasing the need for faster and broader diagnostic solutions.... Read more
Diagnostic Gaps Complicate Bundibugyo Ebola Outbreak Response in Congo
In eastern Democratic Republic of the Congo, communities are confronting a resurgence of Bundibugyo ebolavirus, a rarer species for which no vaccines or treatments have been approved. Ebola is a highly... Read more
Study Finds Hidden Mpox Infections May Drive Ongoing Spread
Mpox continues to circulate despite vaccination, and many cases show no known link to a symptomatic partner. The role of people without symptoms has remained uncertain, limiting clarity on how transmission persists.... Read more
Large-Scale Genomic Surveillance Tracks Resistant Bacteria Across European Hospitals
Antimicrobial resistance (AMR) poses a growing threat to patient safety, with carbapenem-resistant Enterobacterales causing difficult-to-treat infections and leaving clinicians with limited therapeutic options.... Read morePathology
view channel
Rapid AI Tool Predicts Cancer Spatial Gene Expression from Pathology Images
Gene expression profiling can inform tumor biology and treatment selection, but spatial assays remain costly and time-consuming. Results can take weeks and cost thousands of dollars, limiting large-scale... Read more
AI Pathology Test Receives FDA Breakthrough for Bladder Cancer Risk Stratification
Non–muscle invasive bladder cancer has highly variable outcomes, complicating surveillance and treatment planning. Risk assessment typically relies on stage, grade, and tumor size, leaving uncertainty... Read moreTechnology
view channel
AI-Enabled Assistant Unifies Molecular Workflow Planning and Support
Clinical laboratories and research groups face increasingly complex molecular workflows and expanding technical documentation spread across multiple systems. Fragmented digital tools can slow experiment... Read more
AI Tool Automates Validation of Laboratory Software Configuration Changes
Regulated laboratories face heavy documentation and requalification demands when software configurations change, slowing improvements and discouraging beneficial updates. A new capability now automates... Read moreIndustry
view channel
Strategic Collaboration Advances RNA Foundation Models for Precision Oncology
Bulk RNA sequencing is increasingly used to study tumor biology, but standard analyses often reduce results to gene-level summaries that miss important transcript variants and mutation patterns.... Read more








